Based on the Seres Therapeutics Inc stock forecast from 2 analysts, the average analyst target price for Seres Therapeutics Inc is not available over the next 12 months. Seres Therapeutics Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Seres Therapeutics Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Seres Therapeutics Inc’s stock price was USD 8.16. Seres Therapeutics Inc’s stock price has changed by +1,666.23% over the past week, +1,047.20% over the past month and +1,206.44% over the last year.
No recent analyst target price found for Seres Therapeutics Inc
No recent average analyst rating found for Seres Therapeutics Inc
Company Overview Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. The company develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's product candidate is VOWST, the first FDA-approved orally administered microbiome therapeutic. Its product pipeline also includes SER-155, an investigational, oral, live biotherapeutic designed to decolonize gastrointestinal, or GI, pathogens, improve epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, or BSIs, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation, or allo-HSCT. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it develops SER-147, an investigational live biotherapeutic designed to prevent bacterial bloodstream and spontaneous bacterial peritonitis, or SBP, infections in patients with metabolic disease, including clinical liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Read Less
Seres Therapeutics, Inc., a clinical-stage company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. The company develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the...Read More
Frequently Asked Questions About Seres Therapeutics Inc (MCRB) Stock
Based on ratings from 2 analysts Seres Therapeutics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, 1 sell and hold ratings.
Unfortunately we do not have enough data on MCRB's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for MCRB is USD 0.00 over the next 12 months. The maximum analyst target price is USD while the minimum anlayst target price is USD .
Unfortunately we do not have enough data on MCRB's stock to indicate if its overvalued.
The last closing price of MCRB's stock was USD 8.16.
The most recent market capitalization for MCRB is USD 0.11B.
Based on targets from 2 analysts, the average taret price for MCRB is projected at USD 0.00 over the next 12 months.
This means that MCRB's stock price may go up by +0.00% over the next 12 months.
We can't find any ETFs which contains Seres Therapeutics Inc's stock.
As per our most recent records Seres Therapeutics Inc has 103 Employees.
Seres Therapeutics Inc's registered address is 101 Cambridgepark Drive, Cambridge, MA, United States, 02140.
You can get more information about it from Seres Therapeutics Inc's website at https://www.serestherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Seres Therapeutics Inc (MCRB) Stock
Based on ratings from 2 analysts Seres Therapeutics Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, 1 sell and hold ratings.
Unfortunately we do not have enough data on MCRB's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for MCRB is USD 0.00 over the next 12 months. The maximum analyst target price is USD while the minimum anlayst target price is USD .
Unfortunately we do not have enough data on MCRB's stock to indicate if its overvalued.
The last closing price of MCRB's stock was USD 8.16.
The most recent market capitalization for MCRB is USD 0.11B.
Based on targets from 2 analysts, the average taret price for MCRB is projected at USD 0.00 over the next 12 months.
This means that MCRB's stock price may go up by +0.00% over the next 12 months.
We can't find any ETFs which contains Seres Therapeutics Inc's stock.
As per our most recent records Seres Therapeutics Inc has 103 Employees.
Seres Therapeutics Inc's registered address is 101 Cambridgepark Drive, Cambridge, MA, United States, 02140.
You can get more information about it from Seres Therapeutics Inc's website at https://www.serestherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MCRB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
